Statin lipid-lowering therapy for acute myocardial infarction and unstable angina: Efficacy and mechanism of benefit

Mayo Clinic Proceedings

Volumn 77, Issue 10, 2002, Pages 1085-1092

  Wright, R Scott ^a,b   Murphy, Joseph G ^a,b   Bybee, Kevin A ^a   Kopecky, Stephen L ^a,b   LaBlanche, Jean Marc ^c  

^a MAYO CLINIC   (United States)

^b Mayo Physician Alliance for Clinical Trials Rochester   (United States)

^c Heart Hospital   (France)

Author keywords

A to Z; Acs; acute coronary syndrome; acute myocardial infarction; Aggrastat and Zocar trial; Ami; C reactive protein; Cad; Cerivastatin and the Response of IL Interleukin 6 and hs CRP high sensitivity C reactive protein to statin therapy trial; coronary artery disease; Crisp; Crp; Florida; Fluvastatin on Risk Diminishing After Acute Myocardial Infarction; L cad; Ldl; Lipid Coronary Artery Disease; low density lipoprotein; Miracl; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering; Pact; Pravastatin Acute Coronary Trial; Pravastatin or Atorvastatin Evaluation and Infection Therapy Trial Thrombolysis in Myocardial Infarction Grade 22; Pravastatin Turkish Trial; Prevention of Re Infarction with Cerivastatin Study; Princess; Prove it timi 22; Ptt; randomized controlled trial; Rct

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; COLESTYRAMINE; FIBRINOGEN RECEPTOR ANTAGONIST; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTEGRIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; ORBOFIBAN; PLACEBO; PRAVASTATIN; SIBRAFIBAN; SIMVASTATIN; TIROFIBAN;

ACUTE HEART INFARCTION; ANGINA PECTORIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MECHANISM; HEART REINFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0036789256     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/77.10.1085     Document Type: Article

References (58)

1. American Heart Association. 2000 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 1999.
2. Murray CJ, Lopez AD, eds. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, Mass: Harvard School of Public Health; 1996.
3. Shepherd J, Cobbe SM, Ford I, et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary artery disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
4. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
5. Randomised trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
6. Sacks FM, Pfeffer MA, Moye LA, et al. Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
7. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
8. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
9. Waters D. Cholesterol lowering: should it continue to be the last thing we do? Circulation. 1999;99:3215-3217.
10. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than lower cholesterol. Lancet. 1996;348:1079-1082.
11. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998;279:1643-1650.
12. Kinlay S, Selwyn AP, Delagrange D, Creager MA, Libby P, Ganz P. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points. Curr Opin Lipidol. 1996;7:389-397.
13. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-1719.
14. Frenette PS. Locking a leukocyte integrin with statins. N Engl J Med. 2001;345:1419-1421.
15. Pudil R, Pidrman V, Krejsek J, et al. Cytokines and adhesion molecules in the course of acute myocardial infarction. Clin Chim Acta. 1999;280:127-134.
16. Libby P, Sukhova G, Lee RT, Galis ZS. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol. 1995;25(suppl 2):S9-S12.
17. Davies MJ. The pathophysiology of acute coronary syndromes. Heart. 2000;83:361-366.
18. Avellone G, Di Garbo V, Cordova R, Raneli G, De Simone R, Bompiani G. Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIB hyperlipoproteinemia. Curr Ther Res Clin Exp. 1994;55:1335-1344.
19. Wada H, Mori Y, Kaneko T, et al. Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin. Clin Ther. 1992;14:829-834.
20. Koenig W, Hehr R, Ditschuneit HH, et al. Lovastatin alters blood rheology in primary hyperlipoproteinemia: dependence on lipoprotein(a)? J Clin Pharmacol. 1992;32:539-545.
21. Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dL) plus two additional atherosclerotic risk factors. Am J Cardiol. 1993;72:1031-1037.
22. Beigel Y, Fuchs J, Snir M, Green P, Lurie Y, Djaldetti M. Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology. J Clin Pharmacol. 1991;31:512-517.
23. Mayer J, Eller T, Brauer P, et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol. 1992;64:196-201.
24. 2 synthesis in type IIa hypercholesterolemic patients. Atherosclerosis. 1989;79:79-83.
25. Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15:247-251.
26. 2+ and membrane dynamics in patients with primary hypercholesterolemia: effects of pravastatin. Arterioscler Thromb Vasc Biol. 1995;15:759-764.
27. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 1995;92:3172-3177.
28. Lacoste L, Lam JYT. Comparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolemic coronary patients [abstract]. J Am Coll Cardiol. 1996;27(suppl A):413A. Abstract 1045-19.
29. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
30. Tracy RP. Inflammation markers and coronary heart disease. Curr Opin Lipidol. 1999;10:435-441.
31. Ridker PM, Rifai N, Pfeffer MA, et al. Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98:839-844.
32. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E, Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999;100:230-235.
33. Ridker PM, Rifai N, Clearfield M, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-1965.
34. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.
35. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7:687-692.
36. Dupuis J, Tardif J-C, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation. 1999;99:3227-3233.
37. O’Driscoll G, Green D, Taylor R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within I month. Circulation. 1997;95:1126-1131.
38. Laufs U, La Fata V, Plutzky J, Liao K. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation. 1998;97:1129-1135.
39. Bybee KA, Wright RS, Williams BA, Murphy JG, Holmes DR Jr, Kopecky SL. Effect of concomitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute myocardial infarction. Am J Cardiol. 2001;87:771-774.
40. Schiele R, Gitt AK, Heer T, et al. Early statin use in acute myocardial infarction is associated with a reduced hospital mortality: results of the Mitra-2 [abstract]. Circulation. 2000;102(suppl 2): II-435. Abstract 2117.
41. Hamm CW, Heeschen C, Boehm M, White HD. Role of statins in patients with acute coronary syndromes [abstract]. Circulation. 2000;102(suppl 2):11-435. Abstract 2118.
42. Walter DH, Fichtlscherer S, Britten MB, et al. Initiation of statin therapy immediately after stent implantation: profound benefit in patients with acute coronary syndromes [abstract]. Circulation. 2000;102(suppl 2):II-435. Abstract 2119.
43. Stenestrand U, Wallentin L, Swedish Registry of Cardiac Intensive Care. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001;285:430-436.
44. Bybee KA, Wright RS, Powell BD, Williams BA, Vinar JT, Kopecky SL. Differential benefit from treatment with a statin agent at hospital discharge in non-ST elevation MI compared to ST elevation MI [abstract]. Circulation. 2000;102(suppl 2):II-614. Abstract 2977.
45. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 2001;357:1063-1068.
46. Giugliano RP, Antman EM, Thompson SL, McCabe CH, Braunwald E. Lipid lowering drug therapy initiated during hospitalization for acute MI is associated with lower postdischarge 1-year mortality [abstract]. J Am Coll Cardiol. 2001;37(suppl A):316A. Abstract 1053-91.
47. Cannon CP, McCabe CH, Bentley J, Braunwald E. Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: observations from OPUS-TIMI 16 [abstract). J Am Coll Cardiol. 2001;37(suppl A):334A. Abstract 831-2.
48. Newby LK, Kristinsson A, Bhapkar MV, et al. SYMPHONY and 2nd SYMPHONY Investigators. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA. 2002;287:3087-3095.
49. Kayikcioglu M, Turkoglu C, Kultursay H, Evrengul H, Can L. The short term results of combined use of pravastatin with thrombolytic therapy in acute myocardial infarction [abstract]. Circulation. 1999;100(suppl 1):I-303. Abstract 1586.
50. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
51. van Boven AJ, Liem A. Fluvastatin on Risk Diminishing After Acute Myocardial Infarction (FLORIDA). Presented at: American Heart Association Scientific Session 2000; November 12-15, 2000; New Orleans, LA. Available at: www.acc.org/education/online /trials/aha00/florida.htm. Accessibility verified August 21, 2002.
52. Arntz HR, Wunderlich W, Schnitzer L, et al. Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease: results from the Lipid-Coronary Artery Disease (L-CAD) Study [in German]. Z Kardiol. 1999;88:582-590.
53. Arntz HR, Agrawal R, Wunderlich W, et al. Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease IL-CAD] Study). Am J Cardiol. 2000;86:1293-1298.
54. Arntz HR. The case for early statin therapy in acute coronary syndromes. Cardiol Rev. 2002;10:91-96.
55. Blazing MA, De Lemos JA, Dyke CK, Califf RM, Bilheimer D, Braunwald E. The A-to-Z Trial: methods and rationale for a single trial investigating combined with use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J. 2001;142:211-217.
56. Cannon CP, McCabe CH, Belder R, Breen J, Braunwald E. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol. 2002;89:860-861.
57. Fonarow GC, French WJ, Parsons LS, Sun H, Malmgren JA. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial. Infarction 3. Circulation. 2001;103:38-44.
58. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.